Point72 Asset Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,128,551
| Closed | -$85.7M | – | 4343 |
|
|
2025
Q4 | $85.7M | Sell |
1,128,551
-92,091
| -8% | -$6.69M | 0.1% | 225 |
|
|
2025
Q3 | $74.9M | Buy |
+1,220,642
| New | +$63.6M | 0.13% | 185 |
|
|
2025
Q2 | – | Sell |
-1,373,573
| Closed | -$70M | – | 2524 |
|
|
2025
Q1 | $70M | Sell |
1,373,573
-69,789
| -5% | -$3.48M | 0.16% | 156 |
|
|
2024
Q4 | $65.2M | Buy |
1,443,362
+867,502
| +151% | +$37.1M | 0.14% | 164 |
|
|
2024
Q3 | $21.4M | Buy |
575,860
+549,160
| +2,057% | +$18.4M | 0.05% | 397 |
|
|
2024
Q2 | $816K | Buy |
+26,700
| New | +$865K | ﹤0.01% | 1323 |
|
|
2024
Q1 | – | Sell |
-78,100
| Closed | -$2.15M | – | 2532 |
|
|
2023
Q4 | $2.15M | Buy |
+78,100
| New | +$1.79M | 0.01% | 1180 |
|
|
2022
Q1 | – | Sell |
-355,100
| Closed | -$14.1M | – | 1343 |
|
|
2021
Q4 | $14.1M | Sell |
355,100
-164,300
| -32% | -$6.29M | 0.06% | 416 |
|
|
2021
Q3 | $19.3M | Sell |
519,400
-144,715
| -22% | -$5.94M | 0.08% | 317 |
|
|
2021
Q2 | $28.1M | Buy |
664,115
+600,606
| +946% | +$25.7M | 0.13% | 210 |
|
|
2021
Q1 | $3.01M | Sell |
63,509
-883,491
| -93% | -$52.5M | 0.01% | 671 |
|
|
2020
Q4 | $57.8M | Sell |
947,000
-148,829
| -14% | -$8.77M | 0.28% | 76 |
|
|
2020
Q3 | $51.2M | Sell |
1,095,829
-205,945
| -16% | -$10.1M | 0.26% | 94 |
|
|
2020
Q2 | $66.1M | Buy |
1,301,774
+811,174
| +165% | +$39.9M | 0.43% | 54 |
|
|
2020
Q1 | $21.9M | Sell |
490,600
-755,101
| -61% | -$38M | 0.18% | 165 |
|
|
2019
Q4 | $59.8M | Sell |
1,245,701
-1,142,906
| -48% | -$48.6M | 0.31% | 82 |
|
|
2019
Q3 | $80.8M | Sell |
2,388,607
-263,840
| -10% | -$11.5M | 0.5% | 45 |
|
|
2019
Q2 | $119M | Sell |
2,652,447
-252,946
| -9% | -$9.99M | 0.62% | 28 |
|
|
2019
Q1 | $109M | Buy |
2,905,393
+1,440,576
| +98% | +$48.4M | 0.5% | 38 |
|
|
2018
Q4 | $50.3M | Buy |
1,464,817
+1,375,917
| +1,548% | +$49.5M | 0.25% | 112 |
|
|
2018
Q3 | $4.18M | Buy |
+88,900
| New | +$3.68M | 0.02% | 643 |
|
|
2017
Q4 | – | Sell |
-400,000
| Closed | -$8M | – | 1049 |
|
|
2017
Q3 | $8M | Buy |
400,000
+376,300
| +1,588% | +$7.37M | 0.04% | 449 |
|
|
2017
Q2 | $434K | Sell |
23,700
-526,998
| -96% | -$7.1M | ﹤0.01% | 769 |
|
|
2017
Q1 | $5.42M | Buy |
+550,698
| New | +$6.67M | 0.03% | 513 |
|
|
2016
Q4 | – | Sell |
-10,200
| Closed | -$143K | – | 811 |
|
|
2016
Q3 | $143K | Buy |
+10,200
| New | +$82.9K | ﹤0.01% | 685 |
|
|
2015
Q4 | – | Sell |
-426,800
| Closed | -$11.4M | – | 808 |
|
|
2015
Q3 | $11.4M | Buy |
426,800
+270,500
| +173% | +$11.6M | 0.09% | 276 |
|
|
2015
Q2 | $7.52M | Buy |
+156,300
| New | +$9.12M | 0.05% | 377 |
|
|
2015
Q1 | – | Sell |
-169,000
| Closed | -$8.75M | – | 766 |
|
|
2014
Q4 | $8.75M | Buy |
169,000
+12,500
| +8% | +$550K | 0.06% | 349 |
|
|
2014
Q3 | $6.89M | Buy |
+156,500
| New | +$4.9M | 0.05% | 343 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Point72 Asset Management's PTCT Position: Q1 2026 in Review
Point72 Asset Management sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 1,128,551 shares — an estimated $85.7M sold.
Point72 Asset Management first reported a position in PTCT in Q3 2014 and held it in 29 quarters. The position peaked at $119M in Q2 2019. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Point72 Asset Management reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
- Point72 Asset Management sold 1,128,551 PTC Therapeutics shares in Q1 2026, an estimated $85.7M.
- Point72 Asset Management first reported a position in PTC Therapeutics in Q3 2014 and held it in 29 quarters.
- Point72 Asset Management's PTC Therapeutics position peaked at $119M in Q2 2019.
- 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.